A carregar...
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti‐TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1954967/ https://ncbi.nlm.nih.gov/pubmed/17698862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2006.115980 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|